Conexeu Expands Board to Nine With Five Leadership Appointments
CNXU•Conexeu Sciences expanded its board from six to nine directors by appointing Ana Bastiani-Posner, April Burke and Andrew Costa with updated committee assignments. Co-founder David Bogart was named Chief Commercial Officer and Melinda Farina joined the advisory board to accelerate CXU™ platform commercialization post-Nasdaq listing.
1. Board Expansion and Committee Updates
Conexeu Sciences increased its board from six to nine directors with the appointments of Ana Bastiani-Posner, April Burke and Andrew Costa. The company also updated its Audit, Compensation and Nominating & Corporate Governance committee assignments to leverage the new directors’ expertise in healthcare finance, capital markets and growth equity following its Nasdaq listing.
2. Chief Commercial Officer Appointment
Co-founder David Bogart assumes the role of Chief Commercial Officer to lead commercialization and strategic operations for Conexeu’s CXU™ regenerative tissue platform. Bogart has managed over $75 million in capital formation advisory roles and contributed to Conexeu’s IP and regulatory strategy since inception.
3. Advisory Board Addition
Melinda Farina joined Conexeu’s advisory board to support aesthetics and consumer health market strategy. With nearly 30 years in medical aesthetics consulting and as founder of Integrated Aesthetics Consulting Inc. and Beauty Brokers Inc., Farina will guide brand development and market positioning for the company’s preclinical regenerative therapies.
